Pharmacogenomics Journal

Papers
(The median citation count of Pharmacogenomics Journal is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study74
Development of an extensive workflow for comprehensive clinical pharmacogenomic profiling: lessons from a pilot study on 100 whole exome sequencing data36
Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States33
Correction to: A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform31
Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study26
Polygenic risk scores analyses of psychiatric and metabolic traits with antipsychotic-induced weight gain in schizophrenia: an exploratory study25
STRIPE partners in precision medicine series: provider perspective24
Using ChatGPT to predict the future of personalized medicine23
A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care18
Effects and interaction of single nucleotide polymorphisms at the pharmacokinetic/pharmacodynamic site: insights from the Rotterdam study into metformin clinical response and dose titration18
Investigating genetic variants for treatment response to selective serotonin reuptake inhibitors in syndromal factors and side effects among patients with depression in Taiwanese Han population16
Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder15
TMEM158, as plasma cfRNA marker, promotes proliferation and doxorubicin resistance in ovarian cancer12
Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing12
Extreme phenotype sampling and next generation sequencing to identify genetic variants associated with tacrolimus in African American kidney transplant recipients12
Sequencing of genes of drug response in tumor DNA and implications for precision medicine in cancer patients12
The organoid as reliable cancer modeling in personalized medicine, does applicable in precision medicine of head and neck squamous cell carcinoma?11
APF2: an improved ensemble method for pharmacogenomic variant effect prediction11
CYP2C19 point-of-care testing: where are we now and where should we go?10
Clinical and economic outcomes of a pharmacogenomics-enriched comprehensive medication management program in a self-insured employee population9
Network pharmacology prediction, molecular docking and in vitro experiment explored the potential mechanism of Gaoyuan’an capsule in improving hypoxia tolerance9
Knowledge and attitudes of medical and pharmacy students about pharmacogenomics: a systematic review and meta-analysis9
Inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C (rs11706052) and 12-month evolution of the graft function in renal transplant recipients on mycophenolate-based immunosuppress9
Assessment of clinically actionable pharmacogenetic markers to stratify anti-seizure medications9
Targeted next-generation sequencing of genes involved in Warfarin Pharmacodynamics and pharmacokinetics pathways using the Saudi Warfarin Pharmacogenetic study (SWAP)8
Genetic markers of early response to lurasidone in acute schizophrenia7
Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder7
Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects7
Polygenic score analyses on antidepressant response in late-life depression, results from the IRL-GRey study6
Risk of anthracycline-induced cardiac dysfunction in adolescent and young adult (AYA) cancer survivors: role of genetic susceptibility loci6
A blockchain-based framework to support pharmacogenetic data sharing6
Nimodipine-associated standard dose reductions and neurologic outcomes after aneurysmal subarachnoid hemorrhage: the era of pharmacogenomics5
STRIPE partners in precision medicine: regulatory perspective5
Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis5
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)5
An innovative model for pharmacogenomics critical results identification and intervention5
UGT1A1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab5
Evaluation of the EMPAR study population on the basis of metabolic phenotypes of selected pharmacogenes5
Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn’s disease patients5
Bioinformatics driven discovery of small molecule compounds that modulate the FOXM1 and PPARA pathway activities in breast cancer5
Influence of genetic biomarkers on cardiac diseases in childhood cancer survivors: a systematic review5
Benchmarking large language models for replication of guideline-based PGx recommendations5
Non-steroidal anti-inflammatory drug target gene associations with major depressive disorders: a Mendelian randomisation study integrating GWAS, eQTL and mQTL Data4
Exploring pharmacogenetic factors influencing hydroxyurea response in tanzanian sickle cell disease patients: a genomic medicine approach4
Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug4
DNA polymerase gamma variants and hepatotoxicity during maintenance therapy of childhood acute lymphoblastic leukemia: is there a causal relationship?4
The association between the number of HLA risk alleles and drug allergy and its implications for HLA screening – a case-control study4
Genome-wide screening of pharmacogenomic biomarkers in jordanian patients with genetic disorders4
Polygenic scores for cardiovascular risk factors improve estimation of clinical outcomes in CCB treatment compared to pharmacogenetic variants alone4
Association of pharmacodynamic genes with treatment outcomes in major depressive disorder: results from a Sardinian cohort4
Utilisation of drugs with pharmacogenetic recommendations in children in Switzerland4
Implementation of pharmacogenetic testing in pediatric oncology: barriers and facilitators assessment at eight Canadian academic health centres4
Implementing CYP2C19-guided clopidogrel therapy: a scoping review of pharmacogenomic testing services3
The interplay between SLC6A4 and HTR1A genetic variants that may lead to antidepressant failure3
Publisher Correction: Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data3
STRIPE partners in precision medicine series: pharmacist perspective3
Protein network and pathway analysis in a pharmacogenetic study of cyclosporine treatment response in Greek patients with psoriasis3
SLCO1B1*5 is protective against non-senile cataracts in cohort prescribed statins: analysis in a British-South Asian cohort3
Association between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: a meta-analysis3
Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population3
Whole-genome sequencing analysis of clozapine-induced myocarditis3
Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?3
Cytochrome P450-2D6 activity in people with codeine use disorder3
Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?3
KDR genetic predictor of toxicities induced by sorafenib and regorafenib2
Opioid use disorder risk alleles in self-reported assigned African American/Afro-Caribbean and European biogeographical genetic ancestry groups and in males and females2
Pharmacogenomic study—A pilot study of the effect of pharmacogenomic phenotypes on the adequate dosing of verapamil for migraine prevention2
British South Asian ancestry participants views of pharmacogenomics clinical implementation and research: a thematic analysis2
Point of care CYP2C19 genotyping after percutaneous coronary intervention2
Pharmacogenomics in Lebanon: current status, challenges and opportunities2
0.051735877990723